2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapy
2007
Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma
Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews 2007, 33: 146-160. PMID: 17275192, DOI: 10.1016/j.ctrv.2006.08.006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMycosis fungoidesTherapeutic optionsPrimary cutaneous T-cell lymphomaSkin-directed therapiesAggressive clinical courseCurrent therapeutic optionsNon-Hodgkin lymphomaNovel therapeutic targetCritical unmet needWorld Health OrganizationCharacteristic clinicopathologicImmunologic changesCutaneous lymphomasDurable responsesSystemic therapyClinical courseDefinitive treatmentSezary syndromeImmunophenotypic featuresTreatment of cancerAvailable therapiesCell transplantationDisease progression
2005
Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma
Huang Z, Higgins B, Foss F. Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2005, 6: 43-45. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.Peer-Reviewed Original Research